human insulin


( Last Updated : May 4, 2021)
Generic Name:
human insulin
Project Status:
Active
Therapeutic Area:
Diabetes mellitus
Manufacturer:
Eli Lilly Canada Inc.
Brand Name:
Entuzity KwikPen
Project Line:
Reimbursement Review
Project Number:
SR0672-000

Details


Manufacturer Requested Reimbursement Criteria1:
To improve glycemic control in adults and children with diabetes mellitus requiring more than 200 units of insulin per day.
Submission Type:
Initial
Fee Schedule:
Schedule C
Indications:
​To improve glycemic control in adults and children with diabetes mellitus requiring more than 200 units of insulin per day.
Date NOC Issued:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openDecember 22, 2020
Call for patient/clinician input closedFebruary 22, 2021
Clarification:

- Patient input submission received from Diabetes Canada

Submission receivedJanuary 27, 2021
Submission acceptedFebruary 10, 2021
Review initiatedFebruary 11, 2021
Draft CADTH review report(s) provided to sponsor for commentApril 30, 2021
Deadline for sponsors commentsMay 11, 2021
CADTH responses on draft review report(s) provided to sponsorJune 04, 2021
Expert committee meeting (initial)June 16, 2021
Draft recommendation issued to sponsorJune 29, 2021
Draft recommendation posted for stakeholder feedbackJuly 08, 2021
End of feedback periodJuly 22, 2021
Final recommendation issued to sponsor and drug plansAugust 05, 2021
Final recommendation posted
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)
CADTH review report(s) posted